0001104659-17-033537.txt : 20170517
0001104659-17-033537.hdr.sgml : 20170517
20170517190118
ACCESSION NUMBER: 0001104659-17-033537
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170216
FILED AS OF DATE: 20170517
DATE AS OF CHANGE: 20170517
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics AG
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: C4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: LEBERSTRASSE 20
CITY: VIENNA
STATE: C4
ZIP: 1110
BUSINESS PHONE: 43 (0)1 740 93-0
MAIL ADDRESS:
STREET 1: LEBERSTRASSE 20
CITY: VIENNA
STATE: C4
ZIP: 1110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Talbot George Harrison
CENTRAL INDEX KEY: 0001554194
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 17853143
MAIL ADDRESS:
STREET 1: C/O DURATA THERAPEUTICS, INC.
STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
4
1
a4.xml
4
X0306
4
2017-02-16
0
0001641640
Nabriva Therapeutics AG
NBRV
0001554194
Talbot George Harrison
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
1
0
0
0
Common Shares
2017-02-16
4
M
0
502
A
3351
D
Common Shares
2017-02-16
4
M
0
155
A
3506
D
Common Shares
2017-02-16
4
M
0
578
A
4084
D
Common Shares
2017-05-15
4
S
0
50
101.50
D
4034
D
Common Shares
2017-05-16
4
S
0
50
102.268
D
3984
D
Common Shares
2017-05-16
4
S
0
100
103.00
D
3884
D
Stock Option
2017-02-16
4
M
0
502
0
D
2017-09-27
Common Shares
502
0
D
Stock Option
2017-02-16
4
M
0
155
0
D
2017-09-27
Common Shares
155
0
D
Stock Option
2017-02-16
4
M
0
578
0
D
2017-09-27
Common Shares
578
135
D
This transaction is being reported late due to an administrative oversight.
The exercise price was Euro 6.72 per common share.
The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
The price of $101.50 per common share was derived from the sale price on May 15, 2017, of $10.15 per ADS, multiplied by ten.
The price of $102.268 per common share was derived from the sale price on May 16, 2017, of $10.2268 per ADS, multiplied by ten.
The price of $103.00 per common share was derived from the sale price on May 16, 2017, of $10.30 per ADS, multiplied by ten.
This option was granted on June 12, 2009 and is fully vested.
This option was granted on January 29, 2010 and is fully vested.
This option was granted on August 31, 2014. Vesting began on August 31, 2014 and ends on September 30, 2017. Twenty-five percent (25%) of the option vested on December 31, 2014, a further twenty-five percent (25%) of the options vested on December 31, 2015, and the remaining fifty percent (50%) vests on a monthly pro-rata basis over the remaining vesting period.
/s/ Gary L. Sender, by power of attorney
2017-05-17